BLA filing on single-arm CR data with a 25% 12-month KM estimate; approval hinges on whether FDA accepts durability as adequate

Bull

A positive outcome would show the 12-month CR rate stabilizing at or above the 25% KM estimate with a median duration of response that extends meaningfully beyond the preliminary 37.3-week figure, giving FDA a compelling durability profile in a setting of high unmet need. If the agency accepts this single-arm CR data as sufficient for approval — consistent with precedent in BCG-unresponsive NMIBC — the BLA filing proceeds and detalimogene becomes a commercially viable bladder-sparing alternative, unlocking significant value.

Bear

The most likely failure mode is that the 12-month KM estimate decays further from the already-disappointing preliminary 25% figure, particularly given the 39% CR rate observed in the most recent 32-patient subgroup, suggesting a waning effect in later-enrolled patients. Even if the data hold at 25%, FDA could determine that durability is inadequate for single-arm approval without a randomized comparator arm, especially if the agency scrutinizes the declining response trend in the later cohort as a signal of instability in the effect.